Investigation of the Prevalence of Human Parvovirus B19 DNA in Korean Plasmapheresis Donors
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : To ensure the safety of plasma derivatives, some countries have been screening for the human parvovirus B19 (B19V) antigen or DNA in blood donors. We investigated the prevalence of B19V DNA and anti-B19V antibodies in Korean plasmapheresis donors to evaluate the necessity of B19V DNA screening test. Methods : Plasma samples were collected between March and July 2008 from 10,032 plasmapheresis donors. The B19V DNA test was performed using the LightCycler 2.0 (Roche, Germany) with quantification kits. Anti-B19V IgM and IgG were tested in 928 randomly selected samples from the 10,032 donors using recomWell Parvovirus B19 ELISA IgM, IgG assay (Mikrogen, Germany). RecomLine Parvovirus B19 LIA IgG, IgM assay (Mikrogen, Germany) was used to analyze the epitopes of antibodies in donors showing positive results for B19V DNA and anti-B19V antibodies. DNA sequencing was performed to identify the genotypes. Results : The prevalence of B19V DNA was 0.1% (10/10,032). Virus titers in B19V DNA positive donors were less than 105 IU/mL (range: 2.7×101-3.2×104 IU/mL) except for 1 donor (1.33×108 IU/mL). All the isolated B19V DNAs from 6 donors were identified as genotype I. Nine out of 10 B19V DNA positive donors also possessed anti-B19V IgG only or IgG and IgM. The prevalence of anti-B19V IgG was 60.1% (558/928). Conclusions : The prevalence of B19V DNA in Korean blood donors was not high and most donors also possessed neutralizing anti-B19V antibodies. Thus, the implementation of a B19V screening test for Korean blood donors does not appear to be imperative. (Korean J Lab Med 2010;30:58-64)
Abstract
Background : To ensure the safety of plasma derivatives, some countries have been screening for the human parvovirus B19 (B19V) antigen or DNA in blood donors. We investigated the prevalence of B19V DNA and anti-B19V antibodies in Korean plasmapheresis donors to evaluate the necessity of B19V DNA screening test. Methods : Plasma samples were collected between March and July 2008 from 10,032 plasmapheresis donors. The B19V DNA test was performed using the LightCycler 2.0 (Roche, Germany) with quantification kits. Anti-B19V IgM and IgG were tested in 928 randomly selected samples from the 10,032 donors using recomWell Parvovirus B19 ELISA IgM, IgG assay (Mikrogen, Germany). RecomLine Parvovirus B19 LIA IgG, IgM assay (Mikrogen, Germany) was used to analyze the epitopes of antibodies in donors showing positive results for B19V DNA and anti-B19V antibodies. DNA sequencing was performed to identify the genotypes. Results : The prevalence of B19V DNA was 0.1% (10/10,032). Virus titers in B19V DNA positive donors were less than 105 IU/mL (range: 2.7×101-3.2×104 IU/mL) except for 1 donor (1.33×108 IU/mL). All the isolated B19V DNAs from 6 donors were identified as genotype I. Nine out of 10 B19V DNA positive donors also possessed anti-B19V IgG only or IgG and IgM. The prevalence of anti-B19V IgG was 60.1% (558/928). Conclusions : The prevalence of B19V DNA in Korean blood donors was not high and most donors also possessed neutralizing anti-B19V antibodies. Thus, the implementation of a B19V screening test for Korean blood donors does not appear to be imperative. (Korean J Lab Med 2010;30:58-64)
참고문헌 (19)
- Santagostino E, "Eliminating parvovirus B19 from blood products", Lancet, 343, pp.798~799 (1994)
- Yee TT, "Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate", Br J Haematol, 93, pp.457~459 (1996)
- Mosquet B, "Severe hematologic involvement in parvovirus B19 infection. Are antithrombin III injections the origin of the contamination?", Therapie, 49, pp.471~472 (1994)
- Parsyan A, "Human erythrovirus B19 and blood transfusion-an update", Transfus Med, 17, pp.263~278 (2007)
- "Guidance for Industry: Nucleic acid testing (NAT) to reduce the possible risk of human parvovirus B19 transmission by plasma-derived products"[URL]
- Wakamatsu C, "Screening of blood donors for human parvovirus B19 and characterization of the results", Vox Sang, 76, pp.14~21 (1999)
- Schmidt M, "Blood donor screening for parvovirus B19 in Germany and Austria", Transfusion, 47, pp.1775~1782 (2007)
- Brooker M, "Registry of clotting factor concentrate. 8th ed", pp.1~16 (2008), World Federation of Hemophilia
- Lee SO, "Screening of apheresis platelet donors for human parvovirus B19 by gel card test", Korean J Blood Transfusion, 10, pp.215~220 (1999)
- Chun LH, "Human parvovirus B19 and rheumatoid arthritis in Korea", J Korean Rheum Assoc, 8, pp.14~19 (2001)
- Servant A, "De Saint Maur G, Meritet JF, et al. Genetic diversity within human erythroviruses:identification of three genotypes", J Virol, 76, pp.9124~9134 (2002)
- Toan NL, "Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients", J Gen Virol, 87, pp.2941~2949 (2006)
- Blu_mel J, "Parvovirus B19 transmission by heat-treated clotting factor concentrates", Transfusion, 42, pp.1473~1481 (2002)
- Wu CG, "Parvovirus B19 transmission by a high-purity factor VIII concentrate", Transfusion, 45, pp.1003~1010 (2005)
- Kleinman SH, "A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion", Blood, 114, pp.3677~3683 (2009)
- "Parvovirus B19 and HAV screening of Whole blood donations"[URL]
- Kleinman SH, "Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay", Transfusion, 47, pp.1756~1764 (2007)
- "Yuketsujouhou"[URL]
- "Yuketsujouhou"[URL]